secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001493152-22-006506
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell reports Q4 net loss $0.17/sh; cash $55.7M; Roche deal up to $670M
------------------------------------------------------------------------------

- Q4 2021 net loss $29.0M ($0.17/sh) vs net income $2.0M ($0.01/sh) in Q4 2020; FY 2021 net loss $43.0M ($0.26/sh).
- Cash and equivalents $55.7M at Dec 31, 2021; received $50M upfront from Roche/Genentech OpRegen collaboration in Jan 2022.
- Roche/Genentech deal for OpRegen (RG6501) worth up to $670M plus double-digit royalties; four dry AMD patients showed retinal restoration.
- R&D expenses $24.8M in Q4, driven by $21.0M accrual for future obligations to Israel Innovation Authority and Hadasit.
- 2022 milestones include new pipeline program announcement, OPC1 manufacturing improvements, and VAC2 IND submission in 2H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222006506/0001493152-22-006506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222006506/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-006506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer